GeneTx Opens First Clinical Study Site of GTX-102, Potential Angelman Treatment
GeneTx Biotherapeutics has received institutional review board approval to start a Phase 1/2 clinical trial of GTX-102, its investigational therapy for the treatment of Angelman syndrome. While Rush University Medical Center in…